Munich, Germany

Tobias Oelschlaeger

This inventor holds 1 USPTO granted patent. Top assignee: Pharma-Zentrale Gmbh. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tobias Oelschlaeger. Retrieved from https://idiyas.com/inventor/tobias-oelschlaeger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Tobias Oelschlaeger

Introduction

Tobias Oelschlaeger is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of cloning vehicles. His work has implications for various applications in research and industry.

Latest Patents

Oelschlaeger holds 1 patent related to a plasmid-free clone of strain DSM 6601. This invention includes a method for preparing the clone and its use as a cloning vehicle, showcasing his innovative approach to genetic engineering.

Career Highlights

Tobias Oelschlaeger is associated with Pharma-Zentrale GmbH, where he applies his expertise in biotechnology. His role at the company allows him to contribute to advancements in pharmaceutical research and development.

Collaborations

Oelschlaeger has worked alongside notable colleagues such as Jorg Hacker and Sibylle Oswald. Their collaborative efforts have likely enhanced the impact of their research and innovations in the field.

Conclusion

Tobias Oelschlaeger exemplifies the spirit of innovation in biotechnology through his patent and work at Pharma-Zentrale GmbH. His contributions are paving the way for future advancements in cloning and genetic research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…